BIOMAT Database Logo BIOMAT Database Logo

Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. 1996

A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Department of Urology, University of Innsbruck, Austria.

OBJECTIVE Two different studies were performed. The aim of the first study was to define whether the measurement of the ratio between free and total prostate-specific antigen (f/t PSA) in serum may enhance the ability of PSA-based screening for early detection of prostate cancer in men with elevated serum PSA levels. A second study was undertaken to investigate the value of f/t PSA ratio in serum to improve the specificity of prostate cancer screening in men with serum PSA levels between 2.5 and 10.0 ng/mL. METHODS In a retrospective study of 266 men with elevated PSA levels and proven biopsy results, f/t PSA levels were measured using deep frozen serum samples. In a second study we enrolled 158 men with elevated PSA levels according to age reference ranges apparent from our current PSA screening study with additional measurement of the f/t PSA ratio. All study volunteers with a free f/t PSA ratio cutoff point of < or = 22% underwent digital rectal examination, transrectal ultrasonography, and biopsy of the prostate. Free and total PSA levels were measured with the Delfia PSA dual label f/t PSA kit (Wallac Oy Turku, Finland). RESULTS 106 of 158 men with elevated total PSA values between 2.5 and 10.0 ng/mL (group 1) have been further evaluated and 37 prostate cancers were detected. Mean percentage of free PSA was 10% in men with cancer and 22% in men with benign prostatic hyperplasia. Using a f/t PSA ratio of < or = 22% as a biopsy criterion 30% of the negative biopsies could be eliminated while still detecting 98% carcinomas. CONCLUSIONS Measurement of f/t PSA reduces the number of unnecessary biopsies in PSA screening without missing many cancers.

UI MeSH Term Description Entries
D008297 Male Males
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics

Related Publications

A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
[Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
October 2003, Rinsho byori. The Japanese journal of clinical pathology,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less.
November 2015, Iranian journal of public health,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
January 1996, The Prostate. Supplement,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer.
July 1997, European journal of cancer (Oxford, England : 1990),
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
April 1998, British journal of urology,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
[Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
December 1997, Hinyokika kiyo. Acta urologica Japonica,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
On the clinical usefulness of the free-to-total prostate-specific antigen ratio.
January 2006, The International journal of biological markers,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Adding free to total prostate-specific antigen levels in trials of prostate cancer screening.
February 2000, British journal of cancer,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
January 2000, Clinical chemistry,
A Reissigl, and H Klocker, and J Pointner, and K Fink, and W Horninger, and O Ennemoser, and H Strasser, and K Colleselli, and L Höltl, and G Bartsch
Rigorous bicycling does not increase serum levels of total and free prostate-specific antigen (PSA), the free/total PSA ratio, gonadotropin levels, or uroflowmetric parameters.
December 2009, Urology,
Copied contents to your clipboard!